Kisqali (chemical name: ribociclib, formerly called LEE011) was approved by the U.S. Food and Drug Administration (FDA) on March 13, 2017 to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in postmenopausal women. Kisqali is a pill taken by mouth.
In this section you can learn more about:
- How Kisqali Works
- Will Kisqali Work for You?
- What to Expect When Taking Kisqali
- Kisqali Side Effects